Zhongguancun (Daxing) International Nucleic Acid Therapeutics Park and Antisense Nucleic Acid Common Technology Development Joint Laboratory Officially Launched
SicaGene
Oligonucleotide Drug Developer
Click the blue words to follow us
2September 19, 2025, in the morning,Unveiling Ceremony of Zhongguancun (Daxing) International Nucleic Acid Drug Industrial Park and Nucleic Acid Academic Exchange ForumSuccessfully held at China Resources Land Runhui Science Park, the event was attended by Li Zhilei, Second-level Inspector of the Beijing Municipal Science and Technology Commission and Zhongguancun Management Committee, and Zhao Xun, Deputy General Manager of China Resources Land Beijing Company, who delivered speeches. An Xuejun, Member of the Standing Committee of Daxing District Party Committee and Deputy District Chief, Ren Juanjuan, Director of Daxing District Science and Technology Commission, Xue Hui, Deputy Secretary of the Party Committee and General Manager of Biomedical Base Company, Wang Yu, Deputy Director of the Park Development and Construction Department of the Beijing Municipal Science and Technology Commission and Zhongguancun Management Committee, Zheng Meng, Deputy Director of Daxing District Science and Technology Commission, Zhang Dawei, Head of Zhongguancun (Daxing) International Nucleic Acid Drug Industrial Park, along with relevant business segment leaders of China Resources Group, participated in the meeting.
Subsequently,Chen Runsheng, Academician of the Chinese Academy of Sciences, Academician of the International Eurasian Academy of Sciences, Bioinformatician, Founder of Ruibo DecodeIn"Artificial Intelligence and Nucleic Acid Drugs"Themed, an in-depth analysis of how artificial intelligence technology empowers nucleic acid drug research and development;Liang Zicai, Chairman and CEO of RiboBio, and a leading figure in China's small nucleic acid fieldBring"Small Nucleic Acid Drugs Are Becoming the Third Wave of Modern Pharmaceutical Development"'s insightful sharing, interpreting the development trends and market prospects of small nucleic acid drugs;Dr. Wang Chuyun, Head of the Common Technology Platform at Beijing International Nucleic Acid Drug Innovation Center, and Dr. Wang Haisheng, Founder of SicaGeneHeld on siteJoint Laboratory for Nucleic Acid Common Technology Development Signing Ceremony, providing additional significant support for the park in terms of technological innovation and the coordinated development of industry, academia, and research.
About Us
The Common Technology Platform of Beijing International Nucleic Acid Drug Innovation Center is the first specialized carrier in Beijing precisely positioned to support oligonucleotide drug development, providing a full-process service system for major national nucleic acid drug creation, analytical testing, pharmaceutical research, registration submission, and information consultation.
The common technology platform is constructed and operated by Beijing Ouli Ge under the brand "Ouli Bio". The team consists of some of the earliest researchers in China who have engaged in the development and pharmaceutical research of oligonucleotide drugs. The platform includes two major sections: "Biological Research" and "Pharmaceutical Research", enabling a full-process drug development and service system of "Design + Synthesis + Evaluation" on the same platform.
The Common Technology Platform is equipped with public laboratories and office areas, adopting an open-access model. It primarily serves various innovative drug formats such as oligonucleotide drugs, oligonucleotide-antibody conjugate drugs, oligonucleotide-peptide conjugate drugs, and gene-editing drugs. It aims to establish an international benchmark for nucleic acid drug technology platforms, accelerating the industrialization and internationalization of nucleic acid drugs in China.
Platform Contact
Email: hongdan.liu@olipharma.com
Phone: 18210277176 (Manager Liu)
Address: Room 202, 2nd Floor, Building 2, No. 21 Baoshen South Street, Beijing Daxing District Biomedical Industry Base, China
